Home > Reports > Insomnia Treatment Market Analysis, Trends, Forecast Up to 2030

Insomnia Treatment Market

Insomnia Treatment Market: Information by Treatment Type (Drug, Devices), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), and Region – Forecast till 2030

Published On : 12 Oct, 2022
Updated On : 13 Oct, 2022
Table of Content Download Sample

Market Snapshot

Base Year:
2021
Study Period:
2020-2030
CAGR:
6.20 %
Fastest Growing Market:
Europe
Largest Market:
North America

The global insomnia treatment market size was valued at USD 3,221.70 million in 2021. It is projected to reach USD 5536.12 million by 2030, growing at a CAGR of 6.20% during the forecast period (2022-2030). Insomnia typically develops as a comorbidity with other conditions. There is a drive to recognize the occurrence of chronic insomnia as an illness that deserves therapy rather than merely treating the primary disorder, where symptoms of insomnia may go unrecognized or ignored. This acknowledgment is due to the discovery of pathophysiologic alterations and the often-significant accompanying morbidity. Patients with insomnia are more likely to have psychological illnesses, such as sadness and anxiety, increased healthcare use and expenses, lower quality of life, substance abuse, poorer work performance, and more accidents. Some of the reasons anticipated to drive the market are the increased incidence of insomnia, rising stress levels, and growing public knowledge of the numerous treatments available for this illness.

Get more information on this report Download Sample Report

Market Dynamics

Global Insomnia Treatment Market Drivers

Rising Stress Caused by People's Highly Active Lifestyle

Insomnia can also be brought on by stressful life events or trauma, such as divorce, break-up, job loss, or illness of a significant other. The incidence rates for insomnia syndrome were greater among females than males, with a rate of approximately 17.6% compared to 13.9% for good initial sleepers, according to a study conducted by Charles M. Morin et al. and published in the JAMA Network Open Journal in November 2020. People with insomnia may see significant changes in their prognosis and treatment response depending on their condition's long-term consequences.

In the South Asian region, the prevalence of insomnia ranged from 35.4% to 70%, according to the research study by Akibul Islam Chowdhury et al., published in the Journal of Preventive Medicine and Hygiene in January 2021. The percentage of university students who reported having insomnia was 52.1%. Furthermore, since lack of sleep is a common health issue among college students, greater efforts should be made to reduce it. Therefore, it is anticipated that the market for insomnia therapy will experience growth over the forecast period despite rising stress levels brought on by people's highly active lifestyles.

Side Effects Caused by Some Premium and OTC Medications

Alpha-blockers, such as alfuzosin (Uroxatral), doxazosin (Cardura), prazosin (Minipress), silodosin (Rapaflo), terazosin (Hytrin), and tamsulosin (Flomax), have been shown to cause daytime sleepiness or sedation. Memory problems have been linked to a lack of REM sleep, and REM sleep declines significantly with age. Medications known as beta-blockers, such as atenolol (Tenormin), metoprolol (Lopressor, Toprol), carvedilol (Coreg), propranolol (Inderal), timolol (Timoptic), and sotalol, have been associated with nighttime awakenings and nightmares (Betapace). These medications supposedly achieve this by interfering with the nightly secretion of the sleep-regulating hormone melatonin. For instance, Blockers are effective medications used in the treatment of cardiovascular disorders, according to the research paper by Thomas G. Riemer et al., published in the Hypertension Journal in March 2021. However, these blockers are suspected of causing psychiatric adverse events (PAEs), which include sleep disorders, insomnia, and strange dreams.

Global Insomnia Treatment Market Restraint

Mistakes Relating to Insomnia's Seriousness

Insomnia affects a large population yet is often misdiagnosed or neglected. Even while primary care physicians understand the significance of sleep to their patient's well-being, they often fail to address the issue. Given the high prevalence and wide-ranging morbidities of insomnia, healthcare professionals should routinely inquire about patients' sleep issues. According to the AASM (American Academy of Sleep Medicine) report from 2019, insomnia can also prevent someone from giving their best effort at work or school. Also, according to other studies, an employee who suffers from sleeplessness loses about eight days of productivity annually.

Most of the time, the effects are considerably worse than being sleepy during the day. Recent studies have connected sleeplessness to diabetes, congestive heart failure, and high blood pressure. Insomnia's early stages need to be recognized and treated, and much more work has to be done in this area. In addition, actions must be taken to ensure that patients receive treatment that is both effective and in line with the recommendations given by professional experts.

Global Insomnia Treatment Market Opportunities

High Media Device usage before Sleep

Researchers studying sleep and mental health are becoming more aware of the need to modernize methods for comprehending media usage's unique social, emotional, and cognitive effects. In recent years, the use of cell phones has increased, which has led to addiction. Recent research suggests excessive smartphone use may be linked to sadness, anxiety, and poor sleep. Such usage may result in anxiety and depression, affecting sleep. Additionally, it has been claimed that using a phone while in bed at night hurts to sleep. This could be explained by the intense light from electronic gadgets, which disturbs circadian rhythms and eventually reduces sleep quality. Students on campus who are severely depressed and anxious should be closely watched for smartphone addiction. Students whose sleep is disturbed due to technology use may be more likely to exhibit signs of depression, such as difficulty concentrating, a loss of energy, and daytime tiredness.

Segmental Analysis of the Global Insomnia Treatment Market

The global insomnia treatment market is segmented by treatment type and distribution channel.

Based on treatment type, the global insomnia treatment market is bifurcated into drugs and devices.

The drug segment is the highest contributor to the market and is expected to grow at a CAGR of 6.30% during the forecast period. Other drug categories are evaluated, including quetiapine, opiates, barbiturates, melatonin antagonists, antihistamines, antidepressants, and antidepressants. Over-the-counter (OTC) sleep aids are used often by people with insomnia or sometimes weekly. Antihistamines sold over-the-counter (OTC), like doxylamine (Unisom) and diphenhydramine (Benadryl), are frequently used to affect sleeping patterns around the world. However, as these are linked to several anticholinergic adverse effects even at standard doses, they are not advised for sleep disturbances. Barbiturates function as agonists of the brain's GABA (gamma-aminobutyric acid) receptors, which shorten the time it takes for people to fall asleep and prevent them from having rapid eye movement (REM) sleep.

More active sleep technology gadgets have entered the market globally over the last few years. While some of these items also include sleep tracking or monitoring, others are solely intended to promote relaxation and better sleep. Modern insomnia devices provide various methods and strategies, from electrical brain stimulation to guided breathing exercises. However, the distinctive feature of these technologies is that they aim to offer a drug-free approach to addressing insomnia and disturbed sleep symptoms. Other examples of these gadgets are the Dodow, Sleep Shepherd Blue, SR1 Delta Sleeper, Dream Headband, and 2Breathe Sleep Inducer. Furthermore, it is anticipated that the recent clearance of new gadgets will accelerate the segment's growth.

Based on distribution channels, the global insomnia treatment market is bifurcated into hospital pharmacies, retail pharmacies, and other distribution channels.

The retail pharmacies segment owns the highest market share and is expected to grow at a CAGR of 6.10% during the forecast period. Unlike a hospital pharmacy, a retail pharmacy sells medicines directly to patients. Retail pharmacies serve as the main point of contact for many patients seeking medical care and dispense medications for sleep problems. Community pharmacies in underdeveloped nations should not treat sleeplessness as a sickness. History taking, medication counseling, and referral practices in retail pharmacies are limited in all settings, regardless of provider type. This restriction applies to pharmacies in both urban and rural settings.

A hospital pharmacy provides healthcare services such as selecting, preparing, storing, compounding, and distributing medications and medical equipment while advising patients and healthcare professionals on how to use them safely, effectively, and efficiently. Hospital pharmacies are specialized pharmacy areas integrated into patient care in medical facilities. Due to the enormous volume of patients in hospitals, hospital pharmacies are given significantly higher preference by pharmaceutical companies to make essential pharmaceuticals available as soon as possible. A drug distribution system is required in every hospital to provide prescription drugs for each patient. The steps between writing a prescription and giving a patient medication make up the drug distribution system.

Regional Analysis of the Global Insomnia Treatment Market

The global insomnia treatment market is divided into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.

North America Dominates the Global Market

Insomnia Treatment Market Regional Analysis

Regional Growth Insights Request Sample Pages

North America is the most significant shareholder in the global insomnia treatment market and is expected to grow at a CAGR of 5.95% during the forecast period. The growing prevalence of insomnia caused by reasons like stress and lifestyle changes dominates the market for insomnia treatments in the United States. Stress can lead to adjustment insomnia, which may impact up to 20% of adults in the United States each year, according to the American Academy of Sleep Medicine 2020. 30% of kids have behavioral childhood insomnia due to poor sleep patterns. About 3 percent of the population has trouble sleeping due to prescription drugs, substance abuse, physical ailments, or mental health difficulties. Depression, drug withdrawal, obesity, and anemia are some specific causes. However, many organizations are concentrating on developing programs to raise awareness about insomnia and its negative repercussions.

Europe is anticipated to grow at a CAGR of 6.40%, generating USD 1,265.88 million during the forecast period. The market for insomnia treatments is expanding significantly in Germany, the most developed nation in Europe. Insomnia prevalence increased from 2009 to 2016, along with a notable rise in hypnotic prescriptions, according to a study by Chiara Baglioni et al. published in the Journal of Sleep Research 2019. The percentage of adults admitted to hypnotic medicine at least once yearly increased from 13.5 percent in 2009 to 17.3 percent in 2016. According to data, 38% of German individuals suffering from sleeplessness had psychotherapy recommended. These factors are anticipated to drive market growth during the forecast period.

Sleep problems are more common in the elderly. Therefore, it is expected that the need for insomnia treatments for the elderly will rise in the Asia-Pacific region. Numerous adverse effects of insomnia include memory issues, poor performance at work, poorer focus, irritability, accidents brought on by insufficient sleep, and health issues linked to long-term sleep deprivation. According to a 2020 April article titled "Prevalence and related risk factors of insomnia among pregnant women in China," around one-fifth of the pregnant Chinese women in the study cohort experienced clinically severe insomnia, which is typical during pregnancy. As a result, the aging population and the above variables will contribute to the market's expansion over the forecast period.

Africa, the Middle East, and Latin America comprise the LAMEA region. The GCC nations share social and economic backgrounds, health problems, and nearly identical health systems and regulations. The article "The use of hypnotics for primary insomnia in Saudi Arabia: a survey of patients' experiences and attitudes" from 2020 reports the results of a survey of 68 people who have primary insomnia. 64.7% of those surveyed were unsatisfied with their understanding of insomnia, and 97% desired additional details on managing it. This suggests that Saudi patients are ignorant of primary insomnia and its management. Prescription hypnotics are the most common method of treatment. However, non-pharmacological therapies are seldom used, indicating ineffective or excessive reliance on hypnotics.

Competitive Landscape

  • Merck & Co. Inc.
  • Ebb Therapeutics
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Electromedical Products International Inc.
  • Takeda Pharmaceutical Company Ltd
  • Cerêve Inc.
  • Innovative Neurological Devices

Recent Developments

  • February 2022- DAYVIGO, Eisai Limited's newly developed non-sedative prescription drug, was approved for sale in Canada. Eisai Limited is a wholly owned subsidiary of Eisai Inc. (lemborexant). DAYVIGO is indicated for the treatment of insomnia, characterized by difficulties with sleep start and maintenance. DAYVIGO is available in 5 mg and 10 mg dosages, and both are available to patients.
  • January 2022- Royalty Pharma PLC and Minerva Neurosciences Inc. reached an agreement whereby Royalty Pharma will acquire Minerva's seltorexant royalty share. Selotrexant, a selective orexin two receptor antagonist, is in the Phase 3 stage of research as a potential treatment for major depressive disorder (MDD) patients who also battle insomnia.

Global Insomnia Treatment Market: Segmentation

By Treatment Type

  • Drug
  • Devices

By Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Other Distribution Channels

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
Price Starts From
$4250

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

As featured on :

Trusted by Fortune 500
Over 30000+ subscribers